121 related articles for article (PubMed ID: 37363949)
1. Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha-Mutant Endometrial Cancer.
Blanchard Z; Rush CM; Arnesen S; Vahrenkamp JM; Rodriguez AC; Jarboe EA; Brown C; Chang MEK; Flory MR; Mohammed H; Modzelewska K; Lum DH; Gertz J
Mol Cancer Res; 2023 Oct; 21(10):1023-1036. PubMed ID: 37363949
[TBL] [Abstract][Full Text] [Related]
2. Estrogen-independent molecular actions of mutant estrogen receptor 1 in endometrial cancer.
Blanchard Z; Vahrenkamp JM; Berrett KC; Arnesen S; Gertz J
Genome Res; 2019 Sep; 29(9):1429-1441. PubMed ID: 31362937
[TBL] [Abstract][Full Text] [Related]
3. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
4. FOXA1 Reprogramming Dictates Retinoid X Receptor Response in ESR1-Mutant Breast Cancer.
Wu Y; Li Z; Wedn AM; Casey AN; Brown D; Rao SV; Omarjee S; Hooda J; Carroll JS; Gertz J; Atkinson JM; Lee AV; Oesterreich S
Mol Cancer Res; 2023 Jun; 21(6):591-604. PubMed ID: 36930833
[TBL] [Abstract][Full Text] [Related]
5. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
7. Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of
Williams MM; Spoelstra NS; Arnesen S; O'Neill KI; Christenson JL; Reese J; Torkko KC; Goodspeed A; Rosas E; Hanamura T; Sams SB; Li Z; Oesterreich S; Riggins RB; Jacobsen BM; Elias A; Gertz J; Richer JK
Cancer Res; 2021 Feb; 81(3):732-746. PubMed ID: 33184106
[TBL] [Abstract][Full Text] [Related]
8. Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.
Li Z; Wu Y; Yates ME; Tasdemir N; Bahreini A; Chen J; Levine KM; Priedigkeit NM; Nasrazadani A; Ali S; Buluwela L; Arnesen S; Gertz J; Richer JK; Troness B; El-Ashry D; Zhang Q; Gerratana L; Zhang Y; Cristofanilli M; Montanez MA; Sundd P; Wallace CT; Watkins SC; Fumagalli C; Guerini-Rocco E; Zhu L; Tseng GC; Wagle N; Carroll JS; Jank P; Denkert C; Karsten MM; Blohmer JU; Park BH; Lucas PC; Atkinson JM; Lee AV; Oesterreich S
Cancer Res; 2022 Apr; 82(7):1321-1339. PubMed ID: 35078818
[TBL] [Abstract][Full Text] [Related]
9. Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.
Jeselsohn R; Bergholz JS; Pun M; Cornwell M; Liu W; Nardone A; Xiao T; Li W; Qiu X; Buchwalter G; Feiglin A; Abell-Hart K; Fei T; Rao P; Long H; Kwiatkowski N; Zhang T; Gray N; Melchers D; Houtman R; Liu XS; Cohen O; Wagle N; Winer EP; Zhao J; Brown M
Cancer Cell; 2018 Feb; 33(2):173-186.e5. PubMed ID: 29438694
[TBL] [Abstract][Full Text] [Related]
10. ETV4 Is Necessary for Estrogen Signaling and Growth in Endometrial Cancer Cells.
Rodriguez AC; Vahrenkamp JM; Berrett KC; Clark KA; Guillen KP; Scherer SD; Yang CH; Welm BE; Janát-Amsbury MM; Graves BJ; Gertz J
Cancer Res; 2020 Mar; 80(6):1234-1245. PubMed ID: 32046982
[TBL] [Abstract][Full Text] [Related]
11. Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary Effects.
Arnesen S; Blanchard Z; Williams MM; Berrett KC; Li Z; Oesterreich S; Richer JK; Gertz J
Cancer Res; 2021 Feb; 81(3):539-551. PubMed ID: 33184109
[TBL] [Abstract][Full Text] [Related]
12.
Kumar M; Salem K; Michel C; Jeffery JJ; Yan Y; Fowler AM
J Nucl Med; 2019 Sep; 60(9):1247-1252. PubMed ID: 30850489
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
[TBL] [Abstract][Full Text] [Related]
14. Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes.
Jia S; Miedel MT; Ngo M; Hessenius R; Chen N; Wang P; Bahreini A; Li Z; Ding Z; Shun TY; Zuckerman DM; Taylor DL; Puhalla SL; Lee AV; Oesterreich S; Stern AM
Oncology; 2018; 94(3):176-189. PubMed ID: 29306943
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.
Chandarlapaty S; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Voi M; Gnant M; Hortobagyi G; Baselga J; Moynahan ME
JAMA Oncol; 2016 Oct; 2(10):1310-1315. PubMed ID: 27532364
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
Ross DS; Zehir A; Brogi E; Konno F; Krystel-Whittemore M; Edelweiss M; Berger MF; Toy W; Chandarlapaty S; Razavi P; Baselga J; Wen HY
Mod Pathol; 2019 Jan; 32(1):81-87. PubMed ID: 30158597
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
18. Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration.
Wu Y; Li Z; Lee AV; Oesterreich S; Luo B
Breast Cancer Res Treat; 2024 Jun; 205(2):371-386. PubMed ID: 38427312
[TBL] [Abstract][Full Text] [Related]
19. Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.
Harrod A; Lai CF; Goldsbrough I; Simmons GM; Oppermans N; Santos DB; Győrffy B; Allsopp RC; Toghill BJ; Balachandran K; Lawson M; Morrow CJ; Surakala M; Carnevalli LS; Zhang P; Guttery DS; Shaw JA; Coombes RC; Buluwela L; Ali S
Oncogene; 2022 Oct; 41(44):4905-4915. PubMed ID: 36198774
[TBL] [Abstract][Full Text] [Related]
20. Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling.
De Marchi T; Lai CF; Simmons GM; Goldsbrough I; Harrod A; Lam T; Buluwela L; Kjellström S; Brueffer C; Saal LH; Malmström J; Ali S; Niméus E
Sci Rep; 2024 Mar; 14(1):6873. PubMed ID: 38519482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
